Silane-Coated Polyurethane Carrier for Localized Antibody Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating diseases using systemic application of monoclonal antibodies are expensive and associated with severe side effects, and existing devices like TheraSorb require complex cell separation and are costly due to their extravagance and low flow rates.
Innovation Solution
A method of producing a solid coated carrier by incubating a solid carrier with a silane solution, attaching biological material, and embedding it in a coating matrix with substances like peptides, sugars, or PEGs, allowing for defined and stable immobilization of biological materials on the carrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic application of monoclonal antibodies is used to treat diseases, then therapeutic effect is achieved, but severe side effects and high costs occur
Solution Approach 1:
The patent extracts the therapeutic function of antibodies from systemic circulation and localizes it to a specific device within the bloodstream. The device contains immobilized antibodies that remain at the treatment site, providing continuous local therapy without systemic distribution, thereby eliminating side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent introduces a device as an intermediary carrier that holds immobilized antibodies. This device acts as a mediator between the antibody therapy and the patient's bloodstream, allowing controlled local interaction without direct systemic injection of antibodies, thus reducing harmful side effects.
2Reliability
If TheraSorb device with sepharose and polyclonal antibodies is used, then immune substances are removed, but cell separation is required and flow rate is low
Solution Approach 1:
The patent employs a porous polyurethane foam structure as the carrier matrix. This porous material provides high surface area for antibody immobilization while maintaining open channels for blood flow, eliminating the need for complex cell separation steps and enabling high flow rates comparable to native blood circulation.
Solution Approach 2:
The patent creates a composite structure combining polyurethane foam with immobilized monoclonal antibodies. This composite material integrates the mechanical properties of foam (high porosity, structural stability) with the specific therapeutic function of monoclonal antibodies, achieving both high flow rate and stable immobilization without requiring polyclonal antibodies or cell separation.
3Ease of manufacture
If simple antibody administration is used, then treatment is straightforward, but immune reactions inactivate the antibodies
Solution Approach 1:
The patent extracts antibodies from systemic circulation and immobilizes them within a device. This extraction prevents circulating antibodies from encountering immune reactions that would inactivate them, while the device provides continuous local presence of active antibodies for therapeutic effect.
Solution Approach 2:
The patent performs preliminary immobilization of antibodies onto the device matrix before implantation. This preliminary action ensures antibodies are protected from immune inactivation upon contact with the bloodstream, as they are already bound to the carrier and cannot be neutralized by circulating immune factors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and stable immobilization of biological materials, minimizing side effects and costs by allowing for controlled therapy and diagnosis without releasing the biological material into the body fluid, improving stability and enabling sterilization of the carrier.
Implementation Method 1
incubating a solid carrier with a solution comprising 0.1 to 10% (w/w) or (v/v) of at least one silane
Implementation Method 2
embedding it in a coating matrix with substances like peptides, sugars, or PEGs, allowing for defined and stable immobilization of biological materials on the carrier
Data Source
AI summary
The present invention relates to a method of producing a solid coated carrier carrying biological material. Furthermore, the invention relates to a solid coated carrier to which biological material is attached and uses of the solid coated carrier for the preparation of a medical product. Moreover, the invention provides a method for the contacting, filtration or cleaning of blood, lymph or liquor cerebrospinalis of a patient, a method for the diagnosis of a disease and a diagnostic composition.